Table 3.
| Company/Investigator | Cancer target | RNA | NP carrier | Method of administration | Phase | NCT number |
|---|---|---|---|---|---|---|
| Moderna Therapeutics Inc. | Melanoma | mRNA-4157 modified to encode for patient specific tumor-associated antigens or neoantigens | Proprietary lipid NP formulation | IV infusion | II | NCT03897881 |
| BioNTech RNA Pharmaceuticals GmbH | RNAs (RBL001.1, RBL002.2, RBL003.1, RBL004.1) that induce a CD8+ and CD4+ response against melanoma-associated antigens | Liposomes (cholesterol, DOPE, DOTMA) | ID, 7 dose escalation cohorts | II | NCT02410733 | |
| M.D. Anderson Cancer Center | Solid tumors | siRNA against Ephrin type-A receptor 2 (EphA2) | Liposomes (DOPC) |
IV infusion over 120 min on days 1 and 4, repeated every 21 days. | I | NCT01591356 |
| Moderna Therapeutics Inc. | mRNA-4157 modified to encode for patient specific tumor-associated antigens or neoantigens | Proprietary liposome formulation | IM, 9 doses administered every 21 days | I | NCT03313778 | |
| InteRNA Technologies B.V. | miRNA-193a-3p mimic | Proprietary lipid NP formulation | IV infusion for 60 min twice per week | I | NCT04675996 | |
| Genentech Inc. | mRNA RO7198457 encoding patient specific tumor-associated antigens | Proprietary lipoplex formulation | IV infusion in 21-day cycles | I | NCT03289962 | |
| Mina Alpha Limited | Advanced liver cancer | Double stranded RNA to activate CEBPA gene | Amphoteric liposomes (SMARTICLES®) | IV, 1–3 times weekly for 21 days | I | NCT02716012 |
| University Medical Center Groningen | Ovarian cancer | mRNAs encoding for three ovarian cancer tumor associated antigens | Liposomes | IV | I | NCT04163094 |
| BioNTech SE | Triple negative breast cancer | IVAC_WAREHOUSE_bre1_uID and IVAC® MUTANOME _uID, which produce RNAs de novo targeting patient specific tumor-associated antigens/neoantigens | Liposomes | IV | I | NCT02316457 |
| Moderna Therapeutics Inc. | Solid tumors and lymphoma | mRNA-2752 encoding for the OX40 ligand T-cell costimulator, IL-23, and IL-36γ | Proprietary lipid NP | Intratumoral, escalating dose every 2 weeks | I | NCT03739931 |
| Moderna Therapeutics Inc. | Melanoma, colon cancer, gastrointestinal cancer, genitourinary cancer, hepatocellular cancer, relapsed/refractory solid tumor malignancies, lymphoma, ovarian cancer |
mRNA NCI-4650 encoding patient specific tumor-associated antigens mRNA-2416 encoding for a OX40 ligand |
Liposomes (SM-102, DSPC, PEG2000-DMG, cholesterol) |
Intratumoral injection on days 1 and 15 for six 28-day cycles |
I/II | NCT03323398 |
Legend: IM- intramuscular, ID- intradermal, IV- intravenous, DOPE- 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOTMA- 1,2-di-O-octadecenyl-3-trimethylammonium propane, DOPC- 1,2-dioleoyl-sn-glycero-3-phosphocholine, SM-102- sphingomyelin 102, DSPE- 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine, PEG- polyethylene glycol.